Ces radiol. 2018, 72(1):51-57 | DOI: 10.55095/CesRadiol2018/009
The application of the prostatic specific membrane antigene ligand 68Ga-PSMA-11 in imaging of prostatic tumors using PET/CT and PET/MRI - initial experience with tolerance of the applied substance and imaging qualityOriginal article
- 1 Klinika zobrazovacích metod LF UK a FN v Plzni
- 2 Onkologická a radioterapeutická klinika LF UK a FN v Plzni
- 3 Urologická klinika LF UK a FN v Plzni
Aim: Early evaluation of the experience with the application of 68Ga-PSMA-11 in the relation to the tolerance and the evolution of the renal and liver laboratory tests, and in relation to the quality of imaging.
Methods: The sample of 20 males was evaluated, 10 using PET/CT and 10 using PET/MRI. The vital functions during application and than the evolution of the laboratory serum levels of urea, creatinine, AST and ALT were evaluated within one week after radiopharmaceutical applications.
Results: During one-week periprocedural period after radiopharmaceutcal application, there were not noted serious adverse events, in two ptients there were elevated serum creatinine levels above the upper treshold of normal values, in one patient also elevation of AST (previously yet elevated). No application related changes of vital values were noted. All imaging was considered as sufficient for evaluation.
Conclusion: Early experience with the application of 68Ga-PSMA-11 shows, that it does not induce changes of vital values, but in individual cases, there could be noted the changes in renal or liver blood tests, due to the realtion with the own disease development.
Keywords: 68Ga-PSMA-11, prostatic carcinoma, PET/MRI, PET/CT
Grants and funding:
Podpořeno projektem institucionálního výzkumu MZ ČR 00669806 Fakultní nemocnice v Plzni a projektem výzkumu Univerzity Karlovy - PRogRES q39.
Accepted: February 28, 2018; Published: March 1, 2018 Show citation
ACS | AIP | APA | ASA | Harvard | Chicago | Chicago Notes | IEEE | ISO690 | MLA | NLM | Turabian | Vancouver |
References
- Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, Holland-Letz T, Giesel FL, Kratochwil C, Haufe S, Haberkorn U, Zechmann CM. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging 2013; 40(4): 486-495.
Go to original source...
Go to PubMed...
- Afshar-Oromieh A, Haberkorn U, Hadaschik B, Habl G, Eder M, Eisenhut M, Schlemmer HP, Roethke MC. PET/MRI with a 68Ga-PSMA ligand for the detection of prostate cancer. Eur J Nucl Med Mol Imaging 2013; 40(10): 1629-1630.
Go to original source...
Go to PubMed...
- Afshar-Oromieh A, Haberkorn U, Schlemmer HP, Fenchel M, Eder M, Eisenhut M, Hadaschik BA, Kopp-Schneider A, Röthke M. Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience. Eur J Nucl Med Mol Imaging 2014; 41(5): 887-897.
Go to original source...
Go to PubMed...
- Calais J, Fendler WP, Eiber M, Gartmann J, Chu FI, Nickols NG, Reiter RE, Rettig MB, Marks LS, Ahlering TE, Huynh LM, Slavik R, Gupta P, Quon A, Allen-Auerbach MS, Czernin J, Herrmann K. Impact of (68)Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence. J Nucl Med 2018; 59(3): 434-441.
Go to original source...
Go to PubMed...
- Kranzbühler B, Nagel H, Becker AS, Müller J, Huellner M, Stolzmann P, Muehlematter U, Guckenberger M, Kaufmann PA, Eberli D, Burger IA. Clinical performance of 68Ga-PSMA-11 PET/MRI for the detection of recurrent prostate cancer following radical prostatectomy. Eur J Nucl Med Mol Imaging 2018; 45(1): 20-30.
Go to original source...
Go to PubMed...
- Fendler WP, Eiber M, Beheshti M, Bomanji J, Ceci F, Cho S, Giesel F, Haberkorn U, Hope TA, Kopka K, Krause BJ, Mottaghy FM, Schöder H, Sunderland J, Wan S, Wester HJ, Fanti S, Herrmann K. (68)Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol Imaging 2017; 44(6): 1014-1024.
Go to original source...
Go to PubMed...
- Schmuck S, Nordlohne S, von Klot CA, Henkenberens C, Sohns JM, Christiansen H, Wester HJ, Ross TL, Bengel FM, Derlin T. Comparison of standard and delayed imaging to improve the detection rate of [(68)Ga]PSMA I&T PET/CT in patients with biochemical recurrence or prostate-specific antigen persistence after primary therapy for prostate cancer. Eur J Nucl Med Mol Imaging 2017; 44(6): 960-968.
Go to original source...
Go to PubMed...
- Einspieler I, Rauscher I, Düwel C, Krönke M, Rischpler C, Habl G, Dewes S, Ott A, Wester HJ, Schwaiger M, Maurer T, Eiber M. Detection Efficacy of Hybrid (68)Ga-PSMA Ligand PET/CT in Prostate Cancer Patients with Biochemical Recurrence After Primary Radiation Therapy Defined by Phoenix Criteria. J Nucl Med 2017; 58(7): 1081-1087.
Go to original source...
Go to PubMed...
- Uprimny C, Kroiss AS, Decristoforo C, Fritz J, von Guggenberg E, Kendler D, Scarpa L, di Santo G, Roig LG, Maffey-Steffan J, Horninger W, Virgolini IJ. (68)Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour. Eur J Nucl Med Mol Imaging 2017; 44(6): 941-949.
Go to original source...
Go to PubMed...
- Eiber M, Weirich G, Holzapfel K, Souvatzoglou M, Haller B, Rauscher I, Beer AJ, Wester HJ, Gschwend J, Schwaiger M, Maurer T. Simultaneous (68)Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer. Eur Urol 2016; 70(5): 829-836.
Go to original source...
Go to PubMed...
- Herlemann A, Wenter V, Kretschmer A, Thierfelder KM, Bartenstein P, Faber C, Gildehaus FJ, Stief CG, Gratzke C, Fendler WP. (68)Ga-PSMA Positron Emission Tomography/Computed Tomography Provides Accurate Staging of Lymph Node Regions Prior to Lymph Node Dissection in Patients with Prostate Cancer. Eur Urol 2016; 70(4): 553-557.
Go to original source...
Go to PubMed...
This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.